Q-omics provides the consensus-scored MIR3193 profile across patient tissues and cancer cell-line models. MIR3193 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR3193 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, MIR3193 RNA expression shows 10,969 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, THCA, and CCRCC as cancer lineages where MIR3193 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3193 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3193 survival associations across molecular data types. MIR3193 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3193 RNA expression–survival associations across cancer types. High MIR3193 expression shows unfavorable associations in CESC, TGCT, COAD and OV, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR3193 RNA expression.
This table summarizes MIR3193 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3193. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3193 shows lower tumor expression in THCA, LUAD, BRCA, LUSC, KICH and COAD. The THCA box plot shows higher MIR3193 RNA expression in normal versus tumor tissue (log2 FC = −1.417, t-test p = .005).
This table shows molecular features associated with MIR3193 in patient tissues and cancer cell lines. In patient samples, MIR3193 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
